JAAD Case Reports · 2018 · 23 citations · 3 references
MedicineDermatologyPharmacotherapyHypersensitivityImmunopharmacologyInflammationInflammatory DermatosesInflammatory Oral LesionsInflammatory Skin DiseasesInflammatory Skin DisordersPsoriatic ArthritisDrug-induced Lichenoid EruptionLichenoid DermatitisLichenoid Tissue ReactionOral Lichenoid LesionsOral Lichenoid ReactionsProduct Safety ProfilePsoriasis TherapyPsoriatic Disease
Secukinumab (SEK), a fully human anti–interleukin (IL)-17A monoclonal antibody, is effective in the treatment of psoriasis. Although it has a favorable safety profile, 2 cases of associated oral lichen planus (OLP)/lichenoid mucositis have been recently described.1,2
3
Severe, ulcerative, lichenoid mucositis associated with secukinumab
Jordan M. Thompson, Lisa M. Cohen, Catherine S. Yang et al. · JAAD Case Reports · 2016 · 38 citations · Full text
Medicine, Dermatology, Immunology +12